Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

INSPIRATION, 2021 NCT04486508

anticoagulation, intermediate prophylactic dose (n=276) vs. anticoagulant, prophylactic dose (n=286)

randomized controlled trial   some concerns about risk of bias

Studied treatment

intermediate-dose prophylactic anticoagulation
enoxaparin, 1mg/kg daily

Control treatment

standard-dose prophylactic anticoagulation
enoxaparin, 40mg daily

Patients

COVID-19 severe or critically

Method

open-label

10 academic centers in Iran

2 × 2 factorial design comparing intermediate-dose vs standard-dose prophylactic anticoagulation and statin therapy vs matching placebo

Remark